药学与临床研究
藥學與臨床研究
약학여림상연구
PHARMACEUTICAL AND CLINICAL RESEARCH
2014年
3期
268-270
,共3页
坎地沙坦酯氢氯噻嗪%降压疗效%肾功能
坎地沙坦酯氫氯噻嗪%降壓療效%腎功能
감지사탄지경록새진%강압료효%신공능
Candesartan Cilexetil/Hydrochlorothiazide%Antihypertensive effect%Kidney function
目的：以坎地沙坦西酯片为阳性对照药，评价国产坎地沙坦酯氢氯噻嗪胶囊治疗轻、中度原发性高血压的疗效和对肾功能的影响。方法：纳入我院2010年12月至2012年2月期间收治的原发高血压病患者296例，将其随机平均分为2组，停用其他降压药2周（清洗期）后，对照组给予坎地沙坦西酯（必洛斯）片（8 mg/片，口服，每次2片，每日1次）治疗，试验组给予坎地沙坦酯氢氯噻嗪胶囊（16 mg/12.5 mg/粒，口服，每次1粒，每日1次）治疗，分别在治疗前，治疗4周、8周后进行血压测量及尿常规、血钾、血钠、血氯、血肌酐（Cr）、肌酐清除率（Ccr）及尿素氮（BUN）等指标检测。结果：治疗8周后，试验组降压显效率为52.0%，总有效率为82.4%（n=148）；对照组显效率为28.4%，总有效率为68.2%（n=148）；显效率、总有效率两组比较差异有统计学意义（P<0.05）。两组治疗前后尿常规、血钾、血钠、血氯、Cr、 Ccr及BUN与经治疗后两组各指标比较差异无统计学意义（P>0．05）。结论：坎地沙坦酯氢氯噻嗪胶囊对于轻、中度高血压患者的降压疗效优于对照组坎地沙坦西酯片，对肾功能的影响与其相当。
目的：以坎地沙坦西酯片為暘性對照藥，評價國產坎地沙坦酯氫氯噻嗪膠囊治療輕、中度原髮性高血壓的療效和對腎功能的影響。方法：納入我院2010年12月至2012年2月期間收治的原髮高血壓病患者296例，將其隨機平均分為2組，停用其他降壓藥2週（清洗期）後，對照組給予坎地沙坦西酯（必洛斯）片（8 mg/片，口服，每次2片，每日1次）治療，試驗組給予坎地沙坦酯氫氯噻嗪膠囊（16 mg/12.5 mg/粒，口服，每次1粒，每日1次）治療，分彆在治療前，治療4週、8週後進行血壓測量及尿常規、血鉀、血鈉、血氯、血肌酐（Cr）、肌酐清除率（Ccr）及尿素氮（BUN）等指標檢測。結果：治療8週後，試驗組降壓顯效率為52.0%，總有效率為82.4%（n=148）；對照組顯效率為28.4%，總有效率為68.2%（n=148）；顯效率、總有效率兩組比較差異有統計學意義（P<0.05）。兩組治療前後尿常規、血鉀、血鈉、血氯、Cr、 Ccr及BUN與經治療後兩組各指標比較差異無統計學意義（P>0．05）。結論：坎地沙坦酯氫氯噻嗪膠囊對于輕、中度高血壓患者的降壓療效優于對照組坎地沙坦西酯片，對腎功能的影響與其相噹。
목적：이감지사탄서지편위양성대조약，평개국산감지사탄지경록새진효낭치료경、중도원발성고혈압적료효화대신공능적영향。방법：납입아원2010년12월지2012년2월기간수치적원발고혈압병환자296례，장기수궤평균분위2조，정용기타강압약2주（청세기）후，대조조급여감지사탄서지（필락사）편（8 mg/편，구복，매차2편，매일1차）치료，시험조급여감지사탄지경록새진효낭（16 mg/12.5 mg/립，구복，매차1립，매일1차）치료，분별재치료전，치료4주、8주후진행혈압측량급뇨상규、혈갑、혈납、혈록、혈기항（Cr）、기항청제솔（Ccr）급뇨소담（BUN）등지표검측。결과：치료8주후，시험조강압현효솔위52.0%，총유효솔위82.4%（n=148）；대조조현효솔위28.4%，총유효솔위68.2%（n=148）；현효솔、총유효솔량조비교차이유통계학의의（P<0.05）。량조치료전후뇨상규、혈갑、혈납、혈록、Cr、 Ccr급BUN여경치료후량조각지표비교차이무통계학의의（P>0．05）。결론：감지사탄지경록새진효낭대우경、중도고혈압환자적강압료효우우대조조감지사탄서지편，대신공능적영향여기상당。
Objective: To evaluate the domestic Candesartan Cilexetil/Hydrochlorothiazide Capsules, with Candesartan Cilexetil Tablets as the positive control drug, for the curative effects on moderate primary hy-pertension and the influence on renal function. Methods: In our hospital, from December 2010 to February 2012, 296 patients of primary hypertension were admitted, randomly divided into 2 groups and stopped other blood pressure medication for 2 weeks (cleaning period). In the control group, patients were given Candesartan Cilexetil Tablets (8 mg/tablet, p.o, 2 tablets once a day); in the experimental group, patients were given Candesartan Cilexetil/Hydrochlorothiazide Capsules (16 mg/12.5 mg/capsule, p.o, 1 capsule once a day). Before treatment and 4 and 8 weeks after treatment, patients were measured for blood pressure index, urinalysis, blood serum sodium, potassium, chloride, creatinine(Cr), creatinine clearance(Ccr) and urea nitro-gen (BUN), etc. Results: After 8 weeks of treatment, the experimental group showed antihypertensive effi-ciency as 52.0% and total effective rate as 82.4%(n=148); The control group showed efficiency as 28.4%total effective rate as 28.4%(n=148); differences of efficiency and total effective rate between the two groups were statistically significant(P<0.05). The results of urine and blood tests, between the treatment be-fore and after, or between the two groups after treatment, showed no statistically significant differences (P>0.05). Conclusion: Candesartan Cilexetil/Hydrochlorothiazide Capsules in patients with mild-to-moderate hypertension antihypertensive have effects superior to Candesartan Cilexetil Tablets with equivalent influence on renal functions.
